Brokers Offer Predictions for REGN FY2026 Earnings

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) – Equities research analysts at Cantor Fitzgerald issued their FY2026 earnings per share estimates for Regeneron Pharmaceuticals in a research report issued to clients and investors on Monday, June 9th. Cantor Fitzgerald analyst C. Gould expects that the biopharmaceutical company will post earnings of $26.24 per share for the year. Cantor Fitzgerald currently has a “Overweight” rating and a $695.00 price target on the stock. The consensus estimate for Regeneron Pharmaceuticals’ current full-year earnings is $35.92 per share.

Several other analysts have also recently issued reports on REGN. JPMorgan Chase & Co. dropped their target price on Regeneron Pharmaceuticals from $950.00 to $800.00 and set an “overweight” rating on the stock in a research report on Monday. Morgan Stanley dropped their target price on Regeneron Pharmaceuticals from $958.00 to $755.00 and set an “overweight” rating on the stock in a research report on Monday, June 2nd. Truist Financial dropped their target price on Regeneron Pharmaceuticals from $975.00 to $940.00 and set a “buy” rating on the stock in a research report on Wednesday, April 30th. Robert W. Baird decreased their price objective on Regeneron Pharmaceuticals from $759.00 to $652.00 and set a “neutral” rating for the company in a report on Friday, April 25th. Finally, Royal Bank of Canada lowered Regeneron Pharmaceuticals from a “moderate buy” rating to a “hold” rating and set a $662.00 price objective for the company. in a report on Friday, May 30th. One research analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have given a buy rating and three have given a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $836.48.

Regeneron Pharmaceuticals Stock Up 0.6%

Shares of NASDAQ REGN opened at $521.84 on Wednesday. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09. The stock has a market capitalization of $56.34 billion, a PE ratio of 13.63, a price-to-earnings-growth ratio of 2.34 and a beta of 0.31. The stock’s fifty day simple moving average is $563.74 and its two-hundred day simple moving average is $651.53. Regeneron Pharmaceuticals has a 12-month low of $476.49 and a 12-month high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share (EPS) for the quarter, missing the consensus estimate of $8.83 by ($0.61). The company had revenue of $3.03 billion for the quarter, compared to the consensus estimate of $3.40 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The firm’s revenue was down 3.7% compared to the same quarter last year. During the same period last year, the business posted $9.55 EPS.

Regeneron Pharmaceuticals Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, June 6th. Shareholders of record on Tuesday, May 20th were given a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a yield of 0.67%. The ex-dividend date of this dividend was Tuesday, May 20th. Regeneron Pharmaceuticals’s dividend payout ratio is currently 8.96%.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. grew its position in Regeneron Pharmaceuticals by 1.3% during the 1st quarter. Vanguard Group Inc. now owns 9,407,891 shares of the biopharmaceutical company’s stock worth $5,966,767,000 after purchasing an additional 121,545 shares during the period. Capital International Investors grew its position in Regeneron Pharmaceuticals by 41.6% during the 4th quarter. Capital International Investors now owns 4,736,929 shares of the biopharmaceutical company’s stock worth $3,373,859,000 after purchasing an additional 1,390,534 shares during the period. Geode Capital Management LLC grew its position in Regeneron Pharmaceuticals by 6.8% during the 4th quarter. Geode Capital Management LLC now owns 2,427,630 shares of the biopharmaceutical company’s stock worth $1,726,940,000 after purchasing an additional 155,369 shares during the period. Dodge & Cox grew its position in Regeneron Pharmaceuticals by 0.4% during the 4th quarter. Dodge & Cox now owns 2,321,316 shares of the biopharmaceutical company’s stock worth $1,653,543,000 after purchasing an additional 9,381 shares during the period. Finally, Price T Rowe Associates Inc. MD grew its position in shares of Regeneron Pharmaceuticals by 4.3% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 2,175,026 shares of the biopharmaceutical company’s stock valued at $1,379,467,000 after acquiring an additional 89,579 shares during the period. 83.31% of the stock is owned by institutional investors and hedge funds.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.